Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Dec;14(1):2052698.
doi: 10.1080/19490976.2022.2052698.

The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota

Yongrong Zhang  1 , Ashley Saint Fleur  1 , Hanping Feng  1
Affiliations

The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota

Yongrong Zhang et al. Gut Microbes. 2022 Jan-Dec.

Abstract

Clostridioides difficile is the most prevalent pathogen of nosocomial diarrhea. In the United States, over 450,000 cases of C. difficile infection (CDI), responsible for more than 29,000 deaths, are reported annually in recent years. Because of the emergence of hypervirulent strains and strains less susceptible to vancomycin and fidaxomicin, new therapeutics other than antibiotics are urgently needed. The gut microbiome serves as one of the first-line defenses against C. difficile colonization. The use of antibiotics causes gut microbiota dysbiosis and shifts the status from colonization resistance to infection. Hence, novel CDI biotherapeutics capable of reconstituting normal gut microbiota have become a focus of drug development in this field.

Keywords: Clostridioides difficile; biotherapeutics; dysbiosis; microbiota; reconstitution.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
The role of gut microbiota in CDI development.
See this image and copyright information in PMC

References

    1. Hall IC, Denver T, Denver T, Denver T, Denver T.. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. American Journal of Dieseases of Children. 1935;49(2):390–18. doi:10.1001/archpedi.1935.01970020105010. - DOI
    1. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of clostridium difficile as Clostridioides difficile (hall and O’Toole 1935) prévot 1938. Anaerobe. 2016;40:95–99. doi:10.1016/j.anaerobe.2016.06.008. - DOI - PubMed
    1. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. American Journal of Gastroenterology. 2015;110(3):381–390. doi:10.1038/ajg.2015.22. - DOI - PubMed
    1. Orraine L, Yne K, Arny IW, Mir A, Amar Q, Elly PK. Asymptomatic carriage of clostridium difficile and serum levels of IgG antibody against Toxin A. N Engl J Med. 2000;342(6):390–397. doi:10.1056/NEJM200002103420604. - DOI - PubMed
    1. Ozaki E, Kato H, Kita H, Karasawa T, Maegawa T, Koino Y, Matsumoto K, Takada T, Nomoto K, Tanaka R, et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol. 2004;53(2):167–172. doi:10.1099/jmm.0.05376-0. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources